Anzeige
Mehr »
Login
Donnerstag, 31.10.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Neuer Gold Rekord bei knapp 2.800 USD und Übernahme-Zirkus!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
157 Leser
Artikel bewerten:
(1)

Clinical Trials Market Size to Reach $73.33 Billion By 2031 | CAGR 6.8%: The Insight Partners

Clinical Trials Market Experiences Growth Due to Preference for Outsourcing Manufacturing Operations, full analysis by Product, Application, Source, Manufacturing, and Geography

NEW YORK, Oct. 28, 2024 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the Global Clinical Trials Market is observing significant growth owing to the practice of outsourcing clinical studies with a massive rise in the number candidates entering the trials, which signifies flourishing pharmaceutical research & development. The report runs an in-depth analysis of market trends, key players, and future opportunities. The clinical trials market analysis focuses on various platforms and services required for the development of drugs and medical devices, which are expected to contribute to market strength in the coming years.

The Insight Partners Logo

Browse Detailed Analysis: https://www.theinsightpartners.com/reports/clinical-trials-market

Overview of Report Findings

Market Growth:

  1. Market Growth: The clinical trials market value is expected to reach US$ 73.37 billion by 2031 from US 43.37 billion in 2023 at a CAGR of 6.8%. Clinical trials are research studies that involve testing a medical, surgical, or behavioral intervention in human subjects. These trials are the primary way of determining if a new form of treatment or prevention, including a drug, a diet, or a medical device (for example, implantable devices), is safe and effective in humans. Clinical trials are commonly planned to evaluate if a new candidate, a procedure, or a device is more effective or has less harmful side effects than its existing or pre-approved counterparts.

  2. Practice of Outsourcing Clinical Studies with Massive Rise in Number of Trials: The trials are mainly a part of the overall drug development process. According to the National Library of Medicine (NLM), ~52,000 new studies were registered with NLM (ClinicalTrials.gov) in 2020, and the number increased to ~58,000 in 2023. In January 2023, the NLM reported 38,837 active clinical trials in the US and 105,172 active trials worldwide. According to the European Medicine Agency, in the European Union (EU), ~4,000 clinical trials are authorized annually, of which nearly 60% of studies are associated with the pharmaceutical industry. An upsurge in the number of clinical trials can be attributed to the rising prevalence of chronic diseases worldwide, which creates an immense demand for more effective treatments. According to a blog published by Thermo Fisher Scientific, in 2022, CROs executed ~3 out of 4 clinical trials to reassure the clinical programs of drug developers, provide a wealth of expertise, drive time and cost efficiencies, and deliver customized, high-quality data. Thus, the increasing number of clinical trials, and the practice of outsourcing trials to CROs to boost cost-effectiveness and reduce errors are the major factors driving the clinical trials market growth.

  3. AI-Driven Clinical Trials: The adoption of artificial intelligence (AI) offers innovative ways to collect and manage clinical trial data, along with reducing dependency on manual operations. Thus, AI acts as a game changer for life science companies involved in the drug development process. AstraZeneca has collected oncology data, including clinical and imaging data, of more than 100,000 consenting patients for different clinical studies. The Oncology Data Science team at AstraZeneca feeds this data into a system that utilizes AI and other statistical tools to generate novel hypotheses for oncology drug development. To transform the process of oncology data feed, the team is adopting complex datasets for accessibility, interoperability, and reusability of data as per the GO FAIR principles, which emphasize on making data findable, accessible, interoperable, and reusable. Such integration empowers data collection from specific clinical trials and projects to be accessible across the company's drug development teams in compliance with data protection laws. Thus, AI-driven clinical trials are expected to drive the clinical trials market toward growth in the future.

  4. Geographical Insights: In 2023, North America led the market with a substantial revenue share, followed by Europe and APAC. Asia Pacific is expected to register the highest CAGR during the forecast period.

Get Sample Pages in your inbox: https://www.theinsightpartners.com/sample/TIPRE00006203/

Market Segmentation

  1. Based on study design, the clinical trials market is bifurcated into interventional trials and expanded access trials. The interventional trials segment held a larger market share in 2023.
  2. By indication, the market is segmented into cardiovascular diseases, oncological conditions, neurological disorders, autoimmune diseases/inflammation, pain management, diabetes, obesity, metabolic disorders, and others. The oncological conditions segment held the largest market share in 2023.
  3. Based on phase, the clinical trials market is divided into Phase I, Phase II, and Phase III. The Phase II segment held the largest market share in 2023.
  4. The clinical trials market is segmented into five major regions: North America, Europe, APAC, Middle East and Africa, and South and Central America.

Get Sample PDF Copy: https://www.theinsightpartners.com/sample/TIPRE00006203/

Competitive Strategy and Development

  1. Key Players: A few of the major companies operating in the clinical trials market include IQVIA Holdings Inc, Parexel International Corporation, IXICO Plc, Charles River Laboratories Inc, ICON Plc, WuXi AppTec Co Ltd, SGS SA, Syneos Health Inc, SIRO Clinpharm Private Limited, Thermo Fisher Scientific Inc, Laboratory Corp of America Holdings, CliniRx, Caidya, Oracle Corp, and Medpace.

  2. Trending Topics: Electronic Patient-Reported Outcomes, Contract Research Organizations, ADMET Testing, and Pre-Clinical Trials

Global Headlines on Organoid Market

  1. Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance
  2. Syneos Health and Haystack Health Partner to Accelerate Clinical Trials with AI
  3. Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea
  4. CROs dMed and Clinipace Merge to Accelerate Customer Success

Purchase Premium Copy of Clinical Trials Market Growth Report (2021-2031) at: https://www.theinsightpartners.com/buy/TIPRE00006203/

Conclusion

Advancements in technologies, burgeoning demand for innovative therapies, and growing focus on patient-centric care and approaches bolster the clinical trial market progress. The clinical trial market landscape is becoming more competitive and complex with continuously transforming regulatory environments and growing collaborations. Increasing focus on using decentralized and hybrid clinical trials over traditional clinical trial methods is expected to generate valuable opportunities in the clinical trials market during the forecast period.

The report from The Insight Partners provides several stakeholders-including drug manufacturers, medical device manufacturers, contract research organizations, medical device component manufacturers, and API manufacturers-with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities.

Check out more related reports by The Insight Partners:

Argentina and Global Clinical Trials Market Analysis Report & Growth Outlook 2028

Interventional ENT Devices Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

Interventional Spine Devices Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

Neurological Biomarkers Market Report 2031 by Segments, Geography, Dynamics, Recent Developments, and Strategic Insights

Neurological Disorder Drugs Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

Diabetes Care Devices And Drugs Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

Diabetes Drug Therapy Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person:
Ankit Mathur
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/organoids-market
Browse more
The Insight Partners Pharmaceuticals Industry Research Reports

Logo: https://mma.prnewswire.com/media/2520492/The_Insight_Partners_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/clinical-trials-market-size-to-reach-73-33-billion-by-2031--cagr-6-8-the-insight-partners-302288484.html

© 2024 PR Newswire
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.